Rallybio
RLYB
47 hedge funds and large institutions have $209M invested in Rallybio in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
8% more capital invested
Capital invested by funds: $194M → $209M (+$14.9M)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.05% less ownership
Funds ownership: 10.81% → 10.76% (-0.05%)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$2.52M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.96M |
| 3 |
State Street
Boston,
Massachusetts
|
+$849K |
| 4 |
Goldman Sachs
New York
|
+$212K |
| 5 |
BlackRock
New York
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.48M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$2.35M |
| 3 |
Walleye Capital
New York
|
-$416K |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$373K |
| 5 |
Renaissance Technologies
New York
|
-$368K |
RLYB Hedge Fund Activity: Q2 2022 in Review
47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q2 2022, worth a combined $209M — up 7.7% from $194M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RLYB positions and 5 closed out — a net gain of 1 holder — while 14 added to existing stakes and 17 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $2.52M. The largest seller was Tekla Capital Management, cutting an estimated $2.48M.
- 47 institutional investors held Rallybio (RLYB) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $209M of Rallybio stock for Q2 2022, up 7.7% quarter-over-quarter.
- 6 funds opened new Rallybio positions in Q2 2022 and 5 closed out, a net change of +1 holder.
- The largest Rallybio buyer in Q2 2022 was VR Adviser, an estimated $2.52M added.
- The largest Rallybio seller in Q2 2022 was Tekla Capital Management, an estimated $2.48M sold.
Based on aggregated 13F filings for Q2 2022.